Drugs / Donislecel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03791567 | — | type 1 diabetes mellitus | CellTrans Inc. | Approved for marketing | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donislecel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03791567 ↗ |
| Known as | Lantidra | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594332 ↗ |
| Modality | Cell therapy | “The drug product consists of allogeneic human islets of Langerhans (islets) in serum-free transplant medium (indicator-free CMRL 1066 medium with HEPES, without sodium...” NCT03791567 ↗ |